Novel Broad-spectrum Antimalarials

Summary

Principal Investigator: Victor Melendez
Abstract: DESCRIPTION (provided by applicant): In the current age of drug resistance, antimalarial choices are inadequate. In order to support the recent eradication agenda, new generations of both chemoprophylactic and chemotherapeutic antimalarials need to meet the following target product profiles: 1) efficacy against multidrug-resistant malaria;2) activity against pre- erythrocytic parasites to prevent infection;3) efficacy against gametocytes for transmission blocking;4) ability to prevent relapse by targeting the hypnozoite forms of the parasites. We have discovered a novel antimalarial acridone chemotype with broad- spectrum activity against both liver stage and blood stage malaria, with potential to be effective against gametocytes and hypnozoites as well. Our proposed work in this application seeks to develop novel, potent, safe, and inexpensive antimalarial drugs for both prevention and treatment of malaria, thus supporting world-wide elimination of the disease. The specific goal of this project is to conduct lead optimization studies to produce candidates for full preclinical testing that retain the broad-spectrum features and demonstrate enhanced efficacy, safety and pharmacokinetic profiles that warrant further development;to investigate the propensity for drug resistance to selected acridone candidates and identify the molecular target(s) through whole genome sequencing and analysis;and to explore mode of action(s) for these broad-spectrum antimalarial acridones using functional assays and bioanalytical approaches.
Funding Period: 2012-04-01 - 2017-03-31
more information: NIH RePORT

Detail Information

Research Grants30

  1. New infection-related proteins of Plasmodium sporozoites and liver stages
    Stefan H I Kappe; Fiscal Year: 2013
    ..Identifying major liver stage-host hepatocyte interactions and elucidating their functional significance will reveal fundamental principles of malaria parasite liver infection and provide new avenues for preventive drug design. ..
  2. Small molecule protein-glycan inhib. as malaria transmission-blocking therapuetic
    RHOEL DAVID RAMOS DINGLASAN; Fiscal Year: 2013
    ....
  3. Lead optimization of DHODH inhibitors for malaria
    Margaret A Phillips; Fiscal Year: 2013
    ..Successful completion of these aims will identify additional DHODH inhibitors with the potential to be advanced for the treatment of malaria. ..